These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 1689807)
1. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902 [TBL] [Abstract][Full Text] [Related]
3. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis. Kris MG; Tyson LB; Clark RA; Gralla RJ Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282 [TBL] [Abstract][Full Text] [Related]
4. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394 [TBL] [Abstract][Full Text] [Related]
5. [Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin]. Suminaga M; Furue H; Taguchi T; Ota K; Niitani H; Tsukagoshi S; Ariyoshi Y; Ikeda M; Ohta J; Akasaka Y Gan To Kagaku Ryoho; 1992 Aug; 19(9):1333-45. PubMed ID: 1386975 [TBL] [Abstract][Full Text] [Related]
6. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739 [TBL] [Abstract][Full Text] [Related]
7. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting. Marty M Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898 [TBL] [Abstract][Full Text] [Related]
8. Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research. Tonato M Eur J Cancer; 1991; 27 Suppl 1():S12-4; discussion S22. PubMed ID: 1831628 [TBL] [Abstract][Full Text] [Related]
9. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of SN-307 (ondansetron), given intravenously in the treatment of nausea and vomiting caused by anticancer drugs including cisplatin--a placebo-controlled, double-blind comparative study]. Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M Gan To Kagaku Ryoho; 1992 Oct; 19(12):2071-84. PubMed ID: 1417015 [TBL] [Abstract][Full Text] [Related]
11. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation]. Jeremić B Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832 [TBL] [Abstract][Full Text] [Related]
12. Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy. Hainsworth JD; Omura GA; Khojasteh A; Bryson JC; Finn AL Am J Clin Oncol; 1991 Aug; 14(4):336-40. PubMed ID: 1830716 [TBL] [Abstract][Full Text] [Related]
13. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400 [TBL] [Abstract][Full Text] [Related]
14. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488 [TBL] [Abstract][Full Text] [Related]
15. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859 [TBL] [Abstract][Full Text] [Related]
16. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy. Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047 [TBL] [Abstract][Full Text] [Related]
17. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience. Sorbe BG Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123 [TBL] [Abstract][Full Text] [Related]
18. [Anti-emetic effect and safety of single dose of ondansetron injection in double-blind comparison study with placebo]. Ohta J; Taguchi T; Furue H; Niitani H; Ota K; Tsukagoshi S; Ariyoshi Y; Ikeda M; Akasaka Y; Suminaga M Gan To Kagaku Ryoho; 1992 Oct; 19(12):2041-55. PubMed ID: 1417013 [TBL] [Abstract][Full Text] [Related]
19. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study]. Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]